Blood plasma market seen reaching $54.2 billion by 2033

Persistence Market Research projects the global blood plasma market will grow from $33.5 billion in 2026 to $54.2 billion by 2033, driven by demand for plasma-derived therapies and expanding collection networks. North America remains the largest market, while Asia Pacific is emerging as a high-growth region.

Why it matters: - Blood plasma underpins therapies used for chronic, rare and life-threatening conditions. - Rising demand for immunoglobulins, albumin and coagulation factors is expanding the market across developed and emerging economies. - Faster fractionation and broader plasma donation programs are improving supply and product availability.

What happened: - Persistence Market Research projects the global blood plasma market will reach $54.2 billion by 2033 from $33.5 billion in 2026. - The forecast implies 7.1% compound annual growth from 2026 to 2033. - The report identifies immunoglobulin products as the leading product segment. - Hospitals and specialty clinics remain the largest end-user segments. - North America leads the market because of its plasma collection infrastructure, reimbursement policies and concentration of major manufacturers. - The report includes a $3148 sample report link: More information.

The details: - Blood plasma is the base for immunoglobulins, albumin, coagulation factors and other plasma-derived proteins. - Immunoglobulins are used widely for autoimmune diseases, neurological disorders and primary immune deficiencies. - Albumin demand is supported by surgical procedures, trauma care and liver disease management. - Hospitals dominate end-user demand because of higher patient volumes, advanced diagnostics and specialized treatment programs. - Specialty clinics are growing as personalized treatment approaches spread. - Research institutions support clinical studies that expand plasma-based uses. - North America also benefits from strong donation awareness, leading collection centers and continued product innovation. - Europe is a major market due to higher healthcare spending, more diagnosis of immune-related disorders and adoption of plasma-derived medicines. - Asia Pacific is growing quickly as healthcare infrastructure improves, access to specialized care expands and investment increases in plasma collection and biopharmaceutical manufacturing. - The report says increasing incidence of chronic diseases, autoimmune disorders and immune deficiencies is a primary growth driver. - The report also points to stronger awareness among healthcare professionals about immunoglobulin therapies. - Plasma fractionation advances are improving manufacturing efficiency, product safety and supply capacity. - Government awareness campaigns and healthcare investment are supporting plasma donation programs. - The market opportunity extends to new uses in neurological disorders, rare diseases and inflammatory conditions. - Emerging economies offer additional growth potential as collection centers expand and partnerships deepen. - The full report is available here: Buy the full report.

Between the lines: - The market outlook reflects a broader shift toward biologic therapies that can address complex and long-duration diseases. - North American leadership suggests plasma supply chains and reimbursement policy still shape access as much as clinical need. - Asia Pacific's growth profile points to an uneven global market where manufacturing and collection capacity remain strategic advantages.

What's next: - Plasma collection networks are likely to keep expanding as demand rises. - Manufacturers are expected to invest further in fractionation technology and broader therapeutic development. - Research into new plasma-derived uses could widen the patient base and support future revenue growth. - Key companies in the market include CSL Behring, Grifols, Takeda Pharmaceutical Company, Kedrion Biopharma, Octapharma, Biotest, China Biologic Products Holdings, LFB Group, Sanquin Plasma Products and ADMA Biologics.